Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts

Iqtidar Hanif, Shervin Assassi, Maureen D. Mayes, Zsuzsanna H. McMahan, Meng Zhang, Julio Charles, John M. VanBuren, Jessica S. Alvey, Kimia Ghaffari, Elana J. Bernstein, Flavia V. Castelino, Lorinda Chung, Luke Evnin, Tracy M. Frech, Jessica K. Gordon, Faye N. Hant, Laura K. Hummers, Dinesh Khanna, Kimberly S. Lakin, Dorota Lebiedz-OdrobinaYiming Luo, Ashima Makol, Jerry A. Molitor, Duncan F. Moore, Carrie Richardson, Nora Sandorfi, Ami A. Shah, Ankoor Shah, Victoria K. Shanmugam, Virginia D. Steen, Elizabeth R. Volkmann, Carleigh Zahn, Brian Skaug*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Objective: Raynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts. Methods: All patient data in the Genetics vs Environment in Scleroderma Outcomes Study (GENISOS) and Collaborative National Quality and Efficacy Registry (CONQUER) cohorts were reviewed. Both studies enrolled patients within five years of the first non-RP symptom. Results: In GENISOS and CONQUER, respectively, 194 (44.2%) of 439 and 292 (31.1%) of 938 patients had a non-RP initial symptom, most commonly puffy fingers/hands. Black patients had a non-RP symptom before RP more commonly than patients in other race and ethnicity categories. Non-RP first patients were more likely than RP first patients to have diffuse cutaneous involvement and joint contractures at enrollment and had a higher prevalence of RNA polymerase III antibody positivity. Conclusion: In two large US cohorts, >30% of patients began to manifest SSc with puffy fingers/hands or other symptoms, without the “warning sign” of RP as their initial symptom. These patients presented with more severe skin and musculoskeletal disease on average, highlighting the importance of early recognition. The most common autoantibody associated with this presentation was RNA polymerase III. These results should be considered in efforts to recognize SSc in its earliest stages. Puffy fingers/hands, even in the absence of RP, should prompt consideration of early SSc and testing for ANA and SSc-associated autoantibodies, including RNA polymerase III.

Original languageEnglish (US)
Pages (from-to)1585-1595
Number of pages11
JournalArthritis and Rheumatology
Volume77
Issue number11
DOIs
StatePublished - Nov 2025

Funding

The Collaborative National Quality and Efficacy Registry (CONQUER) consortium was supported by the Scleroderma Research Foundation. Dr Assassi's work was supported by the Department of Defense (DOD; grant W81XWH‐22‐1‐0162) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH (grant R01‐AR‐081280). Dr Bernstein's work was supported by the NIAMS, NIH (grant K23‐AR‐07511); the National Heart, Lung, and Blood Institute, NIH (grant RO1‐HL‐164758); and the DOD (grant W81XWH‐22‐1‐0163). Dr A. A. Shah's work was supported by the NIAMS, NIH (grant K24‐AR‐080217). Dr Skaug's work was supported by the NIAMS, NIH (grant K08‐AR‐081402) and by an Investigator Award from the Rheumatology Research Foundation.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Hand Swelling and Other Non–Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts'. Together they form a unique fingerprint.

Cite this